2023-508209-25-00招募中1 期
A study to learn how safe and tolerable odronextamab and cemiplimab are in adult patients with B-cell malignancies
Regeneron Pharmaceuticals Inc.13 个研究点 分布在 3 个国家目标入组 58 人开始时间: 2024年3月25日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 58
- 试验地点
- 13
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Medical Affairs
Scientific
Regeneron Pharmaceuticals Inc.
研究点 (13)
Loading locations...
相似试验
招募中
2 期
Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD).2022-501250-12-01Sparingvision17
招募中
1 期
A study to assess the safety, tolerability, uptake and efficacy of VMX-C001 in healthy volunteers.2023-507059-32-00VarmX B.V., VarmX B.V.48
招募中
3 期
A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of chemotherapy for participants with follicular lymphomaFollicular lymphoma2022-502660-20-00Regeneron Pharmaceuticals Inc.225
招募中
1 期
A trial to investigate the safety and pharmacokinetics of GRT6019 in healthy male participants.2025-523587-20-00Gruenenthal GmbH24
招募中
2 期
A Phase 2a Study of the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis2024-520201-39-00Odyssey Therapeutics Inc.47